Effects of stromal cell-derived factor-1 and survivin gene polymorphisms on gastric cancer risk

Liarmakopoulos,Emmanouil; Theodoropoulos,George; Vaiopoulou,Anna; Rizos,Spyros; Aravantinos,Gerasimos; Kouraklis,Gregory; Nikiteas,Nikolaos; Gazouli,Maria

doi:10.3892/mmr.2012.1247

Effects of stromal cell-derived factor-1 and survivin gene polymorphisms on gastric cancer risk

Authors:
- Emmanouil Liarmakopoulos
- George Theodoropoulos
- Anna Vaiopoulou
- Spyros Rizos
- Gerasimos Aravantinos
- Gregory Kouraklis
- Nikolaos Nikiteas
- Maria Gazouli
View Affiliations

Affiliations: First Surgical Department, Tzaneion Hospital, Piraeus, Greece, First Propaedeutic Surgical Department, Hippocration University Hospital, Athens, Greece , Laboratory of Biology, School of Medicine, University of Athens, Athens, Greece, Third Clinic of Pathology-Oncology, Agioi Anargyroi Oncology Hospital, Athens, Greece, Second Propaedeutic Surgical Department, Laiko University Hospital, Athens, Greece
Published online on: December 21, 2012 https://doi.org/10.3892/mmr.2012.1247
Pages: 887-892

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Stromal-cell derived factor-1 (SDF-1), a CXC chemokine, is important for growth, angiogenesis and metastasis of tumor cells. The SDF1-3'A polymorphism has been investigated in various types of cancer; however, no information is currently available on its role in gastric cancer. Survivin is a member of the inhibitor of apoptosis family of proteins and has a genetic polymorphism (-31G/C) located in the CDE/CHR repressor element of its promoter. In this study, 88 gastric cancer patients and 480 normal healthy control subjects were investigated for the genotype and allelic SDF1-3'A and survivin -31G/C frequencies using polymerase chain reaction‑restriction fragment length polymorphism. The SDF1-3'A genotype frequencies for GG, GA and AA were 44.32, 48.86 and 6.92% in patients and 42.71, 47.71 and 9.58% in healthy subjects, respectively. GA+AA genotype frequency and A allele distribution were not identified as significantly different between gastric cancer cases and controls. The survivin frequencies for GG, GC and CC were 20.45, 50 and 29.54% in patients and 33.96, 45 and 21.04% in healthy subjects, respectively. The C carriers (GC+CC genotype) and the C allele were over-represented among the gastric cancer cases (P=0.013 and P=0.0083, respectively). Overall, no statistically significant association was identified for SDF-1 and survivin gene examined alleles and genotypes and any parameter investigated, (e.g., stage, differentiation status and survival). The survivin promoter -31G/C polymorphism may confer an increased susceptibility to gastric cancer, while the SDF1-3'A polymorphism may not be a candidate genetic variant to select individuals at higher risk of developing gastric cancer.

View Figures

View References

1	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
2	Noffsinger A and Waxman I: Preinvasive neoplasia in the stomach: diagnosis and treatment. Clin Gastroenterol Hepatol. 9:1018–1023. 2007. View Article : Google Scholar : PubMed/NCBI
3	Resende C, Ristimäki A and Machado JC: Genetic and epigenetic alteration in gastric carcinogenesis. Helicobacter. 1:34–39. 2010. View Article : Google Scholar : PubMed/NCBI
4	Venkateshwari A, Krishnaveni D, Venugopal S, Shashikumar P, Vidyasagar A and Jyothy A: Helicobacter pylori infection in relation to gastric cancer progression. Indian J Cancer. 48:94–98. 2011. View Article : Google Scholar
5	Loh M, Koh KX, Yeo BH, et al: Meta-analysis of genetic polymorphisms and gastric cancer risk: variability in associations according to race. Eur J Cancer. 45:2562–2568. 2009. View Article : Google Scholar : PubMed/NCBI
6	Gao L, Nieters A and Brenner H: Cell proliferation-related genetic polymorphisms and gastric cancer risk: systematic review and meta-analysis. Eur J Hum Genet. 17:1658–1667. 2009. View Article : Google Scholar : PubMed/NCBI
7	Tashiro K, Tada H, Heilker R, Shirozu M, Nakano T and Honjo T: Signal sequence trap: a cloning strategy for secreted proteins and type I membrane proteins. Science. 261:600–603. 1993. View Article : Google Scholar : PubMed/NCBI
8	Nagasawa T, Kikutani H and Kishimoto T: Molecular cloning and structure of a pre-B-cell growth-stimulating factor. Proc Natl Acad Sci USA. 91:2305–2309. 1994. View Article : Google Scholar : PubMed/NCBI
9	Bleul CC, Fuhlbrigge RC, Casasnovas JM, Aiuti A and Springer TA: A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J Exp Med. 184:1101–1109. 1996. View Article : Google Scholar : PubMed/NCBI
10	Bleul CC, Farzan M, Choe H, et al: The lymphocyte chemoattractant SDF-1 is a ligand for LELESTR/fusin and blocks HIV-1 entry. Nature. 382:829–833. 1996. View Article : Google Scholar : PubMed/NCBI
11	Tachibana K, Hirota S, Iizasa H, et al: The chemokine receptor CXCRCR4 is essential for vascularization of the gastrointestinal tract. Nature. 393:591–594. 1998. View Article : Google Scholar : PubMed/NCBI
12	Vandercappellen J, Van Damme J and Struyf S: The role of CXC chemokines and their receptors in cancer. Cancer Lett. 267:226–244. 2008. View Article : Google Scholar : PubMed/NCBI
13	Kucia M, Reca R, Miekus K, et al: Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells. 23:879–894. 2005. View Article : Google Scholar : PubMed/NCBI
14	Zheng K, Li HY, Su XL, Wang XY, Tian T, Li F and Ren GS: Chemokine receptor CXCR7 regulates the invasion, angiogenesis and tumor growth of human hepatocellular carcinoma cells. J Exp Clin Cancer Res. 29:312010. View Article : Google Scholar : PubMed/NCBI
15	Watanabe MA, de Oliveira Cavassin GG, Orellana MD, Milanezi CM, Voltarelli JC, Kashima S and Covas DT: SDF-1 gene polymorphisms and syncytia induction in Brazilian HIV-1 infected individuals. Microb Pathog. 35:31–34. 2003. View Article : Google Scholar : PubMed/NCBI
16	Dean M, Carrington M and O'Brien SJ: Balanced polymorphism selected by genetic versus infectious human disease. Annu Rev Genomics Hum Genet. 3:263–292. 2002. View Article : Google Scholar : PubMed/NCBI
17	Voevodin A, Samilchuk E and Dashti S: Frequencies of SDF-1 chemokine, CCRCCRCCR-5 and CCRCCRCCR-2 chemokine receptor gene alleles conferring resistance to human immunodeficiency virus type 1 and AIDS in Kuwaitis. J Med Virol. 58:54–58. 1999. View Article : Google Scholar : PubMed/NCBI
18	Winkler C, Modi W, Smith MW, et al: Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC). Science. 279:389–393. 1998.
19	Sei S, O'Neill DP, Stewart SK, et al: Increased level of stromal cell-derived factor-1 mRNA in peripheral blood mononuclear cells from children with AIDS-related lymphoma. Cancer Res. 61:5028–5037. 2001.PubMed/NCBI
20	Ide A, Kawasaki E, Abiru N, et al: Stromal-cell derived factor-1 chemokine gene variant is associated with type 1 diabetes age at onset in Japanese population. Hum Immunol. 64:973–978. 2003. View Article : Google Scholar : PubMed/NCBI
21	Hassan S, Baccarelli A, Salvucci O and Basik M: Plasma stromal cell-derived factor-1: host derived marker predictive of distant metastasis in breast cancer. Clin Cancer Res. 14:446–454. 2008. View Article : Google Scholar : PubMed/NCBI
22	Khademi B, Razmkhah M, Erfani N, Gharagozloo M and Ghaderi A: SDF-1 and CCR5 genes polymorphism in patients with head and neck cancer. Pathol Oncol Res. 14:45–50. 2008. View Article : Google Scholar : PubMed/NCBI
23	Hirata H, Hinoda Y, Kikuno N, et al: CXCL12 G801A polymorphism is a risk factor for sporadic prostate cancer susceptibility. Clin Cancer Res. 13:5056–5062. 2007. View Article : Google Scholar : PubMed/NCBI
24	Nahon P, Sutton A, Rufat P, et al: Chemokine system polymorphisms, survival and hepatocellular carcinoma occurrence in patients with hepatitis C virus-related cirrhosis. World J Gastroenterol. 14:713–719. 2008. View Article : Google Scholar : PubMed/NCBI
25	Razmkhah M, Doroudchi M, Ghayumi SM, Erfani N and Ghaderi A: Stromal cell-derived factor-1 (SDF-1) gene and susceptibility of Iranian patients with lung cancer. Lung Cancer. 49:311–315. 2005. View Article : Google Scholar : PubMed/NCBI
26	Coelho A, Calcada C, Catarino R, Pinto D, Fonseca G and Medeiros R: CXCLCL12-3′ A polymorphism and lung cancer metastases protection: new perspectives in immunotherapy? Cancer Immunol Immunother. 55:639–643. 2006.
27	Razmkhah M, Talei AR, Doroudchi M, Khalili-Azad T and Ghaderi A: Stromal cell-derived factor-1 (SDF-1) alleles and susceptibility to breast carcinoma. Cancer Lett. 225:261–266. 2005. View Article : Google Scholar : PubMed/NCBI
28	Dimberg J, Hugander A, Lofgren S and Wagsater D: Polymorphism and circulating levels of the chemokine CXCLCL12 in colorectal cancer patients. Int J Mol Med. 19:11–15. 2007.
29	Hidalgo-Pascual M, Galan JJ, Chaves-Conde M, et al: Analysis of CXCL12 3′UTR G>A polymorphism in colorectal cancer. Oncol Rep. 18:1583–1587. 2007.
30	Theodoropoulos GE, Panoussopoulos GS, Michalopoulos NV, et al: Analysis of the stromal cell-derived factor 1-3′A gene polymorphism in pancreatic cancer. Mol Med Report. 3:693–698. 2010.
31	Ambrosini G, Adida C and Alteri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 3:917–921. 1997. View Article : Google Scholar : PubMed/NCBI
32	Deveraux QL and Reed JC: IAP family proteins - suppressors of apoptosis. Genes Dev. 13:239–252. 1999. View Article : Google Scholar : PubMed/NCBI
33	Li F, Ambrosini G, Chu EY, et al: Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 396:580–584. 1998. View Article : Google Scholar : PubMed/NCBI
34	Altieri DC: The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med. 7:542–547. 2001. View Article : Google Scholar : PubMed/NCBI
35	Liston P, Fong WG and Korneluk RG: The inhibitors of apoptosis: there is more to life than Bcl2. Oncogene. 22:8568–8580. 2003. View Article : Google Scholar : PubMed/NCBI
36	Thompson CB: Apoptosis is the pathogenesis and treatment of disease. Science. 267:1456–1462. 1995. View Article : Google Scholar : PubMed/NCBI
37	Raff M: Cell suicide for beginners. Nature. 396:119–122. 1998. View Article : Google Scholar : PubMed/NCBI
38	Tamm I, Wang Y, Sausville E, et al: IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases and anticancer drugs. Cancer Res. 58:5315–5320. 1998.PubMed/NCBI
39	Asanuma K, Moriai R, Yajima T, et al: Survivin as a radioresistance factor in pancreatic cancer. Jpn J Cancer Res. 91:1204–1209. 2000. View Article : Google Scholar : PubMed/NCBI
40	Kawasaki H, Toyoda M, Shinohara H, et al: Expression of survivin correlates with apoptosis, proliferation and angiogenesis during human colorectal tumorigenesis. Cancer. 91:2026–2032. 2001. View Article : Google Scholar : PubMed/NCBI
41	Altieri DC: Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer. 8:61–70. 2008. View Article : Google Scholar : PubMed/NCBI
42	Chen WC, Liu Q, Fu JX and Kang SY: Expression of survivin and its significance in colorectal cancer. World J Gastroenterol. 10:2886–2889. 2004.PubMed/NCBI
43	Falleni M, Pellegrini C, Marchetti A, et al: Survivin gene expression in early-stage non-small cell lung cancer. J Pathol. 200:620–626. 2003. View Article : Google Scholar : PubMed/NCBI
44	Fields AC, Cotsonis G, Sexton D, Santoianni R and Cohen C: Survivin expression in hepatocellular carcinoma: correlation with proliferation, prognostic parameters and outcome. Mod Pathol. 17:1378–1385. 2004. View Article : Google Scholar : PubMed/NCBI
45	Liu BB and Wang WH: Survivin and pancreatic cancer. World J Clin Oncol. 2:164–168. 2011. View Article : Google Scholar : PubMed/NCBI
46	Wang W, Luo H and Wang A: Expression of survivin and correlation with PCNA in osteosarcoma. J Surg Oncol. 93:578–584. 2006. View Article : Google Scholar : PubMed/NCBI
47	Altieri DC, Marchisio PC and Marchisio C: Survivin apoptosis: an interloper between cell death and cell proliferation in cancer. Lab Invest. 79:1327–1333. 1999.PubMed/NCBI
48	Xu Y, Fang F, Ludewig G, Jones G and Jones D: A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells. DNA Cell Biol. 23:527–537. 2004. View Article : Google Scholar
49	Borbély AA, Murvai M, Szarka K, et al: Survivin promoter polymorphism and cervical carcinogenesis. J Clin Pathol. 60:303–306. 2007.
50	Jang JS, Kim KM, Kang KH, et al: Polymorphisms in the survivin gene and the risk of lung cancer. Lung Cancer. 60:31–39. 2008. View Article : Google Scholar : PubMed/NCBI
51	Theodoropoulos GE, Michalopoulos NV, Panoussopoulos SG, Taka S and Gazouli M: Effects of caspase-9 and survivin gene polymorphisms in pancreatic cancer risk and tumor characteristics. Pancreas. 39:976–980. 2010. View Article : Google Scholar : PubMed/NCBI
52	Yang L, Zhu H, Zhou B, et al: The association between the survivin C-31G polymorphism and gastric cancer risk in a Chinese population. Dig Dis Sci. 54:1021–1028. 2008. View Article : Google Scholar : PubMed/NCBI
53	Cheng ZJ, Hu LH and Huang SJ: Correlation of -31G/C polymorphisms of survivin promoter to tumorigenesis of gastric carcinoma. Ai Zheng. 27:258–263. 2008.(In Chinese).
54	Sobin LH and Wittekind C: UICC TNM Classification of Malignant Tumours. 5th edition. Wiley-Liss; New York, NY: 1997
55	Juarez J, Bendall L and Bradstock K: Chemokines and their receptors as therapeutic targets: the role of the SDF-1/CXCR4 axis. Curr Pharm Res. 10:1245–1259. 2004. View Article : Google Scholar : PubMed/NCBI
56	Iwasa S, Yanagawa T, Fan J and Katoh R: Expression of CXCR4 and its ligand SDF-1 in intestinal-type gastric cancer is associated with lymph node and liver metastasis. Anticancer Res. 29:4751–4758. 2009.PubMed/NCBI
57	Ishigami S, Natsugoe S, Okumura H, et al: Clinical implication of CXCL12 in gastric cancer. Ann Surg Oncol. 14:3154–3158. 2007. View Article : Google Scholar : PubMed/NCBI
58	Woo IS, Hong SH, Byun JH, Kang JH, Jeon HM and Choi MG: Circulating stromal cell derived factor-1 is predictive of distant metastasis in gastric carcinoma. Cancer Invest. 26:256–261. 2008. View Article : Google Scholar : PubMed/NCBI
59	Zhao BC, Wang ZJ, Mao WZ, et al: CXCR4/SDF-1 axis is involved in lymph node metastasis of gastric carcinoma. World J Gastroenterol. 17:2389–2396. 2011. View Article : Google Scholar : PubMed/NCBI
60	Wang YH, Chiou HY, Lin CT, et al: Association between survivin gene promoter -31 C/G polymorphism and urothelial carcinoma risk in Taiwanese population. Urology. 73:670–674. 2009. View Article : Google Scholar : PubMed/NCBI
61	Xu Y, Fang F, Ludewig G, et al: A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells. DNA Cell Biol. 23:419–429. 2004. View Article : Google Scholar
62	Xang X, Xiong G, Chen X, et al: Polymorphisms of survivin promoter are associated with risk of esophageal squamous cell carcinoma. J Cancer Res Clin Oncol. 135:1341–1349. 2009. View Article : Google Scholar : PubMed/NCBI
63	Gazouli M, Tzanakis N, Rallis G, et al: Survivin -31G/C promoter polymorphism and sporadic colorectal cancer. Int J Colorectal Dis. 24:145–150. 2009. View Article : Google Scholar : PubMed/NCBI
64	Qin C, Cao Q, Li P, et al: Functional promoter -31G>C variant in survivin gene is associated with risk and progression of renal cell cancer in a Chinese population. PLoS One. 7:e288292012.
65	Yazdani N, Sayahpour FA, Haghpanah V, et al: Survivin gene polymorphism association with papillary thyroid carcinoma. Pathol Res Pract. 208:100–103. 2012. View Article : Google Scholar : PubMed/NCBI
66	Jaiswal PK, Goel A, Mandhani A and Mittal RD: Functional polymorphisms in promoter survivin gene and its association with susceptibility to bladder cancer in North Indian cohort. Mol Biol Rep. 39:5615–5621. 2012. View Article : Google Scholar : PubMed/NCBI
67	Zahedi P, Aminimoghaddam S, Sayahpour FA, et al: Association of survivin gene polymorphism with endometrial cancer. Int J Gynecol Cancer. 22:35–37. 2012. View Article : Google Scholar : PubMed/NCBI
68	Ma F, Zhang H, Zhai Y, et al: Functional polymorphism -31C/G in the promoter of BIRC5 gene and risk of nasopharyngeal carcinoma among chinese. PLoS One. 6:e167482011. View Article : Google Scholar : PubMed/NCBI
69	Upadhyay R, Khurana R, Kumar S, Ghoshal UC and Mittal B: Role of survivin gene promoter polymorphism (-31G>C) in susceptibility and survival of esophageal cancer in northern India. Ann Surg Oncol. 18:880–887. 2011. View Article : Google Scholar
70	Li Y, Wang J, Jiang F, Lin W and Meng W: Association of polymorphisms in survivin gene with the risk of hepatocellular carcinoma in Chinese han population: a case control study. BMC Med Genet. 13:12012. View Article : Google Scholar : PubMed/NCBI
71	Borges BN, Burbano RR and Harada ML: Survivin -31C/G polymorphism and gastric cancer risk in a Brazilian population. Clin Exp Med. 11:189–193. 2011. View Article : Google Scholar : PubMed/NCBI